Dr Vincelette on MYC Expression in Myelofibrosis
Nicole D. Vincelette, PhD, discusses the role of MYC expression in a subgroup of triple-negative myeloproliferative neoplasms.
Source: onclive.com
Myc Expression News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Myc Expression. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Myc Expression Today - Breaking & Trending Today
Phase 1 Trial Set to Explore Efficacy and Safety of KB-0742 in Solid Tumors
Brian Van Tine, MD, PhD, discusses key considerations for understanding the biology of MYC, the rationale for the phase 1 study of KB-0742 in MYC-amplified or -overexpressed relapsed or refractory solid tumors, and patient characteristics that may signal their eligibility for participation in this trial.
Source: onclive.com
Novel CDK9 Inhibitor Under Investigation in Solid Tumors and NHL
Miguel Villalona-Calero, MD, discusses the unique mechanism of action of KB-0742 and the rationale and design of a phase 1 trial investigating the safety and efficacy of KB-0742 in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma.
Source: onclive.com
Preclinical tasquinimod data presented at ASH 2021 available on Active Biotech's website
Lund, December 15, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that preclinical data on its candidate drug tasquinimod, a small molecule immunomodulator, are now available on the
Source: finanznachrichten.de
Active Biotech: New preclinical data on tasquinimod will be presented at the annual meeting of American Society of Hematology (ASH)
Lund, November 4, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that two abstracts with new preclinical data on tasquinimod, a small molecule immunomodulator, have been accepted for presentation
Source: finanznachrichten.de